MediciNova Plans 2010 NDA For Acute Asthma Attack Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. market for the highly selective beta-2 agonist may reach $500 million, MediciNova Chief Development Officer Gammans says.